Sabizabulin is a microtubule disruptor initially developed as an anti-cancer agent that is being repurposed to treat COVID-19. The VERU-111 clinical trial (NCT04842747), which investigates the use of oral sabizabulin on hospitalized patients with COVID-19, is discussed in this touchRESPIRATORY interview with Dr Michael Gordon (HonorHealth Research Institute).
‘Oral sabizabulin reduces mortality in hospitalized patients with COVID-19 at high risk for acute respiratory distress syndrome’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- What is sabizabulin and what is the rationale for its use in the treatment of COVID-19? (00:21)
- What were the aims, design and eligibility criteria of the VERU-111 clinical trial? (02:05)
- What were the primary and secondary endpoints, and how well were they achieved? (04:38)
- What was the safety profile of sabizabulin? (06:57)
- What were the limitations of the study and what further studies are needed? (08:06)
Disclosures: Michael Gordon is a consultant for OnQuality, Viracta, Qualigen, Leaderboard and MorphicTx; he receives grant/research support from Veru, FujiFilm, ATEA, Beigene, Incyte, Kinevant, Redhill and Syndax; he is on the Advisory Board for Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.
Filmed as a highlight of ICEID 2022
Share this Video
Related Videos In COVID-19
Hiam Chemaitelly, ICEID 2022: COVID-19 vaccine effectiveness against SARS-CoV-2 variants
The COVID-19 pandemic remains an international public health emergency, and the emergence of new SARS-CoV-2 variants highlights concerns regarding COVID-19 breakthrough infections. Understanding emerging SARS-CoV-2 variants is especially important as the medical and public health community seeks to contain COVID-19. In this interview, Dr Hiam Chemaitelly (Weill Cornell Medicine-Qatar, Ar-Rayyan, Qatar) talked to us about […]
Leila Atmowihardjo, ERS 2022: Imatinib for Acute Respiratory Distress Syndrome Induced by COVID-19
INVENT COVID was a phase II study, which investigated the efficacy and safety of intravenous imatinib in acute respiratory distress syndrome induced by COVID-19 (Clinical Trials Identifier: NCT04794088). touchRESPIRATORY were delighted to speak with Dr. Leila Atmowihardjo (Amsterdam Medical Centers: Academic Medical Center, Amsterdam, The Netherlands) to discuss the aims, design, eligibility criteria and findings […]
Adrian Martineau, ERS 2022: Antibody Responses to SARS-CoV-2 Vaccines – the COVIDENCE UK Study
This analysis of COVIDENCE UK investigated potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of antibody responses to administration of SARS-CoV-2 vaccination and booster doses. It was a pleasure to talk with Professor Adrian Martineau (Queen Mary University of London, London, UK) around the aims, methodology and patient population of the COVIDENCE UK study and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!